Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology
MILWAUKEE, RICHMOND, Calif., ST LOUIS, PALO ALTO, Calif., and PARIS, July 23 /PRNewswire-FirstCall/ -- Scientists from The Medical College of Wisconsin in Milwaukee, Sangamo Biosciences, Inc., (Nasdaq: SGMO ), Sigma-Aldrich Corporation (Nasdaq: SIAL ), Open Monoclonal Technology...
MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
Phase 3 PROTEGE ENCORE Clinical Trial Initiated
ROCKVILLE, Md. and INDIANAPOLIS, June 16 /PRNewswire/ -- MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY ) today announced that the PROTEGE trial achieved its targeted
patient enrollment. The trial is a pivotal Phase 2/3 clinical study...
Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer
PLX4032 (R7204) Phase I Results Offer Hope of First Highly Effective Drug in Melanoma Along With Companion Diagnostic
BASEL, Switzerland, June 1 /PRNewswire/ -- Roche announced today results from a Phase I study with PLX4032 (R7204) a new, highly selective and promising treatment for patients...
Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Clinical Data Presented at the 2009 ASCO Meeting
INDIANAPOLIS, May 30 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today presented data from a Phase I clinical trial of its vascular targeted
pan-PI3K/mTORC1/2 inhibitor, SF1126...
Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
- Oral presentation on Sandostatin(R) LAR Depot Phase III data shows significant antitumor benefit in patients with advanced neuroendocrine tumors of the midgut
- Early data show that at eight weeks of treatment, Afinitor(R) stabilized or reduced tumor size in 61% of patients with advanced...
Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting
INDIANAPOLIS, May 19 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today announced that it will be reporting Phase I clinical data on its vascular targeted
pan-PI3K/mTORC1/2 inhibitor, SF1126, during the 2009 American Society of Cli...
First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
- Company plans initiation of clinical studies; Data to be presented at AACR -
BATON ROUGE, La., April 21 /PRNewswire/ -- Drug discovery and development company Esperance Pharmaceuticals today presented positive results from the Company's preclinical program that support the initiation of c...
deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Earlier Intervention
REYKJAVIK, Iceland, Feb. 6 /PRNewswire-FirstCall/ -- Scientists at deCODE
genetics (Nasdaq: DCGN ) today present the discovery of two single letter
variations in the sequence of the human genome (SNPs) conferring substantial
increased risk of thyroid cancer. The two SNPs, located on chromoso...
Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
Despite Widespread Use, Formulary Coverage of Targeted
Cancer Therapies is Inconsistent, According to a New Report from Decision Resources
WALTHAM, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and
AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
QUEBEC CITY, Oct. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
(NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on
endocrine therapy and oncology, today reported that it has entered the
second stage of patient recruitment for its Phase 2 trial in ovarian cancer
Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
- New Claims Cover Anti-Viral Applications of Novel Targeted
Agents Under the Company's Anti-Phospholipid Technology Platform -
- Anti-Viral Potential of These New Agents Supported by Recent Studies Presented at American Association of Immunologists Annual Meeting -
TUSTIN, Calif., ...
Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma
SUNNYVALE, Calif., June 5 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc.
(Nasdaq: PCYC ) today announced final data from a Phase 1/2 study showing a
46 percent complete response rate in patients with multiply recurrent
non-Hodgkin's lymphoma (NHL) who were treated with motexafin gadolinium
Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
INDIANAPOLIS, June 4 /PRNewswire/ -- Semafore Pharmaceuticals Inc.
today reported interim data from a Phase I study of its lead product
candidate, SF1126, a targeted
pan-PI3 kinase (PI3K) inhibitor, in patients
with advanced solid tumors. SF1126 is the first PI3 kinase inhibitor to be
Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies
- Results from Gene Identification Studies Presented at ASCO Support
Further Exploration of Possible Tests to Predict Response to Targeted
Therapies for Colon and Breast Cancers -
REDWOOD CITY, Calif., May 31 /PRNewswire-FirstCall/ -- Genomic Health,
Inc. (Nasdaq: GHDX ), ...
Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
SAN MARINO, Calif., May 29 /PRNewswire/ -- Epeius Biotechnologies
( http://www.epeiusbiotech.com ) announced today the results of an on-going
Phase I/II study of Rexin-G for metastatic bone and soft tissue sarcoma (J
Clin Oncol 26: 14509, 2008). Rexin-G is the first and so far only targeted
Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
FRIMLEY, England, May 20 /PRNewswire-FirstCall/ --
- Tasigna(R) (nilotinib) Effective in 77% of Patients Resistant or
Intolerant to Prior Treatment in the Chronic (Early) Phase of Chronic
Myeloid Leukaemia (CML)(1)
- Highly Targeted
Nature of Tasigna(R) Tackles the Root Cause of CML
Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
- Company's TPM Drug Delivery Technology Demonstrates Substantial Increase in Lidocaine Penetration Compared to a Leading Marketed Product -
MELBOURNE, Australia, April 30 /PRNewswire-FirstCall/ -- Phosphagenics
Limited ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today
Semafore's PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
SAN DIEGO, April 14 /PRNewswire/ -- Semafore Pharmaceuticals Inc.
announced today on the occasion of a poster presentation at the 2008 AACR
Annual Meeting that its integrin-targeted PI3 kinase inhibitor, SF1126, was
shown to cause significant tumor regression in combination with rapamycin
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
- Outstanding interim results cause independent data monitoring committee
to immediately share findings; patients on placebo to be offered everolimus - Everolimus (RAD001) tablet, taken once daily, demonstrated highly
effective anti-tumor activity through continuous targeted
inhibition of ...
Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
Company Also Announces Receipt of Fast Track Designation from FDA,
Favorable Scientific Advice from EMEA and Phase 3 Plans for the Non-Small Cell Lung Cancer Monotherapy Indication
SANTA MONICA, Calif., Feb. 26 /PRNewswire/ -- Dr. Giuseppe Giaccone,
Chief of the Medical Onco...
Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
The Next Step Involves Combining the 350+ Targeted
Drugs on the Market and
in Clinical Development with Each Other to Block Key Pathways to Combat
Drug Resistance, Enhance Anticancer Effects, and Expand the Markets for Targeted
LAKE FOREST, Calif., Feb. 19 ...
Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
SAN MARINO, Calif., Dec. 18 /PRNewswire/ -- Epeius Biotechnologies
Corporation announced today their appreciation of the accomplishments of
their contemporaries in 2007, a truly remarkable year in terms of
biomedical research, scholarship, and gonzo journalism. It was a year in
which a definit...
ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
- New Data Presented at American Heart Association Scientific Sessions 2007 -
ORLANDO, Fla., Nov. 6 /PRNewswire/ -- ARCA Discovery, a privately held
biopharmaceutical company, announced today that investigators presented new
data analyses on ARCA Discovery's lea...
Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
MADISON, Wis., Oct. 15 /PRNewswire/ -- Researchers at Baylor College of
Medicine and Roche NimbleGen Inc., a fully integrated part of Roche Applied
Science, today have published details of a highly efficient and
cost-effective method for capturing targeted
regions of the genome via
St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
A new study shows that loss of Arf gene in presence of BCR-ABL mutation
leaves ALL cells vulnerable to the growth-enhancing environment of the bone
marrow, helping cells develop immunity to the anti-leukemia drug imatinib
MEMPHIS, Tenn., Aug. 29 /PRNewswire-USNewswire/ -- Results of a study
Data From Adherex's European Phase Ib/II Trial of ADH-1 to be
Presented at International Symposium on Targeted Anticancer
RESEARCH TRIANGLE PARK, N.C., Mar 8, 2007 (CCNMatthews via COMTEX
News Network) -- Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a
biopharmaceutical company with a broad portfolio of oncology
products under development, today announced that Dr. Antonella
Perotti, MD, Istituto Nazionale dei Tumori ...
News from the Battlefield of Metastatic Cancer: Epeius
Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G)
from the Stone of Chemistry and Physics
SAN MARINO, Calif., June 04, 2007 /PRNewswire/ -- (SEND2PRESS
NEWSWIRE) -- Epeius Biotechnologies Corporation today announced the
publication of a historic landmark in medical oncology and a
definitive benchmark in the emerging field of cancer gene therapy.
The first clinical report of its kind, L...
ApoCell's Cancer Predictive Index Helps Oncologists Select the Most
Effective Targeted Drug Therapy
HOUSTON--(BUSINESS WIRE)--Jun 7, 2007 - ApoCell, Inc. presented the
results of a study conducted by researchers at the University of
Chicago and ApoCell at the 2007 annual meeting of the American
Society of Clinical Oncology (ASCO) held in Chicago in early June.
The study showed that ApoCell's adva...
Algeta Demonstrates Targeted Cancer-killing Potential of Novel
Alpha Particle Linked Antibodies in Leading Medical Journal Blood
Preclinical Studies Show 227Th-rituximab More Effective at
Killing CD20-Positive Lymphoma Cells Than 90Y-tiuxetan-ibritumomab
OSLO, Norway, 14 June 2007 - Algeta ASA (OSE: ALGETA), the
Norwegian cancer therapeutics company, announces that a research
paper showing the potential of its T...
Antisense Pharma: Promising Phase IIb Results of Targeted Therapy
with AP 12009 in Recurrent Anaplastic Astrocytoma
CHICAGO and REGENSBURG - June 21, 2007 - “In anaplastic
astrocytoma, AP 12009 as a monotherapy is actually clearly superior
to temozolomide,” Prof. Albert Wong, M.D., Stanford
University, California, U.S.A. commented on the international Phase
IIb study with the TGF-beta 2-inhibitor AP...
Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
Michael S. Singer, M.D., Ph.D. Harvard Medical School
With over 200,000 new cases and 40,000 deaths per year, breast cancer undoubtedly qualifies as one of Americas most serious health problems. Recently, efforts to develop early detection methods and more effe...
Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases
...nopathy, uveitis, endophthalmitis and retinoblastoma. Working much like an organ-specific transdermal skin patch, the tiny cup isolates the medication targeted
to the eye from being absorbed into the blood stream. This new delivery system is a safe and non-invasive way to deliver effective doses of medication...
Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors
... and Dunn. The practice provides advanced state-of-the-art diagnostic and therapeutic services including administration of chemotherapy, biologic and targeted
therapies, Computed Tomography (CT), Intensity Modulated Radiation Therapy (IMRT), laboratory and pharmacy services, and an extensive clinical trials ...
ARUP Laboratories Applauds FDA's Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer
...r in innovative laboratory research and development, supports the U.S. Food and Drug Administration's (FDA) decision to put KRAS on the label of two targeted
drugs, Vectibix (panitumumab) and Erbitux (cetuximab). On July 17, 2009, the FDA noted that, "retrospective analyses of metastatic colorectal canc...
Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
...ther advanced drug delivery technologies including Cobalamin(TM)-mediated targeted
delivery and oral drug delivery, its proprietary nanopolymer delivery tec...anized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted
to breast cancer; and Thiarabine , a new generation nucleoside analog wh...
Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
...the filing in 2009 of a New Drug Application for picoplatin as a second-line treatment for small cell lung cancer, with approval and commercialization targeted
for 2010," said Robert De Jager, M.D., chief medical officer of Poniard. "More than 1,100 cancer patients have received picoplatin in clinical studies...
R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
...pharmaceutical venture enterprise has been engaged in the development of new drugs under the theme of "Physician-Oriented New Drug Innovation" and has targeted
at ophthalmologic and dermatological diseases against which effective drugs are hard to come by. The company's main product, Rescula(R) eyedrop 0.12%...
National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness
...e binder, has shown potent cancer killing activity, and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted
therapies, in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor groove, interfering with DNA division a...
UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201
...and Personalized Science for US Oncology Research. "We are eager to leverage the US Oncology Research network to support the study."
for the study include adults with histologically documented metastatic breast cancer with measurable disease that is ER-negative, PR-negative, and HER...
Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
...l company focused on the development of pharmaceutical product candidates for the treatment of obesity. Orexigen's lead combination product candidates targeted
for obesity are Contrave(R), which is in Phase III clinical trials, and Empatic(TM) which is in the later stages of Phase II development. Both product...